330 related articles for article (PubMed ID: 26190565)
21. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
22. JCV serology in time: 3 years of follow-up.
Cambron M; Hadhoum N; Duhin E; Lacour A; Chouraki A; Vermersch P
Acta Neurol Scand; 2017 Jul; 136(1):54-58. PubMed ID: 27766611
[TBL] [Abstract][Full Text] [Related]
23. Natalizumab: risk stratification of individual patients with multiple sclerosis.
Tur C; Montalban X
CNS Drugs; 2014 Jul; 28(7):641-8. PubMed ID: 24942634
[TBL] [Abstract][Full Text] [Related]
24. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Warnke C; Ramanujam R; Plavina T; Bergström T; Goelz S; Subramanyam M; Kockum I; Rahbar A; Kieseier BC; Holmén C; Olsson T; Hillert J; Fogdell-Hahn A
J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1199-205. PubMed ID: 23463870
[TBL] [Abstract][Full Text] [Related]
25. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
[TBL] [Abstract][Full Text] [Related]
26. Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters.
Schwab N; Schneider-Hohendorf T; Hoyt T; Gross CC; Meuth SG; Klotz L; Foley JF; Wiendl H
Mult Scler; 2018 Apr; 24(5):563-573. PubMed ID: 28847222
[TBL] [Abstract][Full Text] [Related]
27. Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial.
Bozic C; Subramanyam M; Richman S; Plavina T; Zhang A; Ticho B
Eur J Neurol; 2014 Feb; 21(2):299-304. PubMed ID: 24894998
[TBL] [Abstract][Full Text] [Related]
28. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.
Kolcava J; Hulova M; Benesova Y; Bednarik J; Stourac P
Mult Scler Relat Disord; 2019 May; 30():187-191. PubMed ID: 30785075
[TBL] [Abstract][Full Text] [Related]
29. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R;
PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580
[TBL] [Abstract][Full Text] [Related]
30. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
Sørensen PS; Bertolotto A; Edan G; Giovannoni G; Gold R; Havrdova E; Kappos L; Kieseier BC; Montalban X; Olsson T
Mult Scler; 2012 Feb; 18(2):143-52. PubMed ID: 22312009
[TBL] [Abstract][Full Text] [Related]
31. Improving risk-stratification of natalizumab-associated PML.
Tugemann B; Berger JR
Ann Clin Transl Neurol; 2021 Mar; 8(3):696-703. PubMed ID: 33539683
[TBL] [Abstract][Full Text] [Related]
32. Anti-JC virus seroprevalence in a Finnish MS cohort.
Kolasa M; Hagman S; Verkkoniemi-Ahola A; Airas L; Koivisto K; Elovaara I
Acta Neurol Scand; 2016 May; 133(5):391-7. PubMed ID: 26347001
[TBL] [Abstract][Full Text] [Related]
33. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Rudick RA; O'Connor PW; Polman CH; Goodman AD; Ray SS; Griffith NM; Jurgensen SA; Gorelik L; Forrestal F; Sandrock AW; Goelz SE
Ann Neurol; 2010 Sep; 68(3):304-10. PubMed ID: 20737514
[TBL] [Abstract][Full Text] [Related]
34. [[Natalizumab therapy, 2013].
Karácsony M; Bencsik K; Vécsei L
Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
[TBL] [Abstract][Full Text] [Related]
35. Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica.
Paz SPC; Branco L; Pereira MAC; Spessotto C; Fragoso YD
Epidemiol Health; 2018; 40():e2018001. PubMed ID: 29370683
[TBL] [Abstract][Full Text] [Related]
36. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
Vukusic S; Rollot F; Casey R; Pique J; Marignier R; Mathey G; Edan G; Brassat D; Ruet A; De Sèze J; Maillart E; Zéphir H; Labauge P; Derache N; Lebrun-Frenay C; Moreau T; Wiertlewski S; Berger E; Moisset X; Rico-Lamy A; Stankoff B; Bensa C; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Vaillant M; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Tourbah A; Guennoc AM; Hankiewicz K; Patry I; Nifle C; Maubeuge N; Labeyrie C; Vermersch P; Laplaud DA;
JAMA Neurol; 2020 Jan; 77(1):94-102. PubMed ID: 31479149
[TBL] [Abstract][Full Text] [Related]
37. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy.
Outteryck O; Ongagna JC; Duhamel A; Zéphir H; Collongues N; Lacour A; Fleury MC; Berteloot AS; Blanc F; Giroux M; Vermersch P; de Sèze J
J Neurol; 2012 Nov; 259(11):2293-8. PubMed ID: 22527227
[TBL] [Abstract][Full Text] [Related]
38. John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.
van Kempen ZLE; Leurs CE; de Vries A; Vennegoor A; Rispens T; Wattjes MP; Killestein J
Eur J Neurol; 2017 Sep; 24(9):1196-1199. PubMed ID: 28707781
[TBL] [Abstract][Full Text] [Related]
39. Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy.
Borchardt J; Berger JR
Mult Scler Relat Disord; 2016 Jul; 8():145-50. PubMed ID: 27456891
[TBL] [Abstract][Full Text] [Related]
40. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance.
Kågström S; Fält A; Berglund A; Piehl F; Olsson T; Lycke J
Mult Scler Relat Disord; 2021 May; 50():102842. PubMed ID: 33610957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
